Single-Cell Atlas of the Whole Human Lung

First integrated Human Lung Cell Atlas provides insights into lung diseases.

By combining data from nearly 40 studies, an international team of researchers, including TGen’s Dr. Nicholas Banovich, created the first integrated single-cell atlas of the lung, revealing rare cell types and highlighting cellular differences between healthy people. In addition, the study found common cell states between lung fibrosis, cancer and COVID-19, offering new ways of understanding lung disease, which could help identify new therapeutic targets.

Continue reading

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B

HEMGENIX®, the first and only FDA approved gene therapy for hemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus standard of care, and reduce or eliminate the need for prophylactic treatment in 94% of patients (51 out of 54) after a one-time infusionContinue reading

CSBI Releases the 2023 Life Sciences Workforce Trends Report at BIO International Convention

BOSTON, MASS., U.S.A., June 7, 2023/EINPresswire.com/ — The Coalition of State Bioscience Institutes (CSBI) releases the 2023 Life Sciences Workforce Trends Report with TEConomy Partners this week at the 2023 BIO International Convention in Boston. The biennial report provides a national snapshot of the most pressing current and anticipated talent needs of the nation’s dynamic life science industry. This year’s report distills a set of key themes sourced from 185 executive interviews and nearly 700 survey responses from companies in eighteen states and Puerto Rico, as well as an assessment of nearly 2.8M job postings from life science companies over the last four years.Continue reading

ABRC Request for Grant Applications Now Open

The Arizona Biomedical Research Centre announced today that it is now accepting Letters of Intent (LOI) for a new cohort of research grants. The LOI is Phase One of a two-phase process. LOI will be accepted through June 28, 2023. Once the letters are reviewed and scored, select applicants will be invited to submit a full application.Continue reading